ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Update on Aveed (Nebido- testosterone undecanoate- long acting testosterone)
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 17164" data-attributes="member: 3"><p><strong></strong></p><p><strong><strong><a href="http://scholar.google.com/scholar_url?url=http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2015.RE.11.FRI-132&hl=en&sa=X&scisig=AAGBfm1yZaXU-LlC7E7PIyADSCe2Kz4V9Q&nossl=1&oi=scholaralrt" target="_blank">FRI-132: Effects of Continuous Treatment up to 11 Years with <strong>Testosterone Undecanoate Injections (TU) in 115 Hypogonadal <strong>Men on Hormonal, Anthropometric and</strong></strong></a></strong></strong></p><p></p><p></p><p></p><p><strong>Abstract:</strong><strong>Introduction:</strong></p><p>The longest-term follow-up on testosterone replacement therapy (TRT) in hypogonadal men in the literature is 6 years. In this registry study, we assessed effects of TRT beyond this period.</p><p><strong>Methods:</strong></p><p>Single-center, cumulative, prospective, registry study of 262 hypogonadal men receiving TU for up to 11 years. Cut-off for total testosterone (T): ≤ 12 nmol/L (~350 ng/dl). In 147 men, TRT had been temporarily discontinued due to reimbursement issues or diagnosis of prostate cancer. In 115 men reported here, TRT was never interrupted for up to 11 years. 115 men were treated for a minimum of 4 years, 114 for 5, 97 for 6, 70 for 7, 57 for 8, 48 for 9, and 23 for 10 years. 4 patients dropped out, 2 due to relocation, 2 were lost to follow-up for unknown reasons. Measures were taken at every other visit. Results at the end of 10 years follow-up are reported.</p><p><strong>Results:</strong></p><p>Mean age was 59.05 ± 9.36 years (min.: 19; max.: 80).</p><p>Total T increased from 7.84 ± 2.34 nmol/L to trough levels (measured prior to the following injection) between 17 and 20 nmol/L, free T from 150.31 ± 65.24 to 400-500 pmol/L, and SHBG decreased from 40.12 ± 20.73 to 33.11 ± 22.14 nmol/L (p<0.0001).</p><p>Mean waist circumference decreased from 106.47 ± 8.72 to 92.33 ± 5.32 cm. The decrease was statistically significant vs baseline (p<0.0001) and significant vs previous year for the first 7 years. Mean weight decreased from 97.3 ± 12.88 to 84.65 ± 7.04 kg. The decrease was statistically significant vs baseline (p<0.0001) and significant vs previous year for the first 8 years. Mean BMI decreased from 30.81 ± 4.33 to 27.06 ± 2.49 kg/m[SUP]2[/SUP] The decrease was statistically significant vs baseline (p<0.0001) and significant vs previous year for the first 8 years. Weight reduction was progressive and accumulated to 18.51 ± 6.46% after 10 years. The reduction of waist circumference was 11.98 ± 5.03%.</p><p>Total cholesterol (TC) decreased from 251.15 ± 46.77 to 172.02 ± 12.09 mg/dl (p<0.0001 vs baseline, statistical significance vs previous year for the first 7 years), LDL from 156.9 ± 25.43 to 98.09 ± 17.62 (p<0.0001 vs baseline, statistical significance vs previous year for the first 3 years), triglycerides (TG) from 235.72 ± 89.26 to 158.04 ± 20.99 (p<0.0001 vs baseline, statistical significance vs previous year for the first 4 years). HDL increased from 42.41 ± 12.61 to 56.52 ± 6.34 mg/dl (p<0.0001 vs baseline, statistical significance vs previous year for the first 3 years).</p><p>TC:HDL ratio improved from 6.59 ± 2.82 to 3.08 ± 0.33 (p<0.0001). Non-HDL cholesterol decreased from 208.74 ± 52.35 to 115.5 ± 11.31 mg/dl (p<0.0001, statistical significance vs previous year for the first 7 years). TG:HDL ratio improved from 6.24 ± 3.53 to 2.82 ± 0.38 (p<0.0001).</p><p>No major adverse cardiovascular event (MACE) occurred during the entire observation time.</p><p><strong>Conclusions:</strong></p><p>Long-term TRT improved anthropometric and lipid parameters in hypogonadal men in a meaningful and sustained fashion.</p><p>Disclosure: AAY: Investigator, Bayer Schering Pharma. GD: statistical analyses, Bayer Schering Pharma. FS: Employee, Bayer Schering Pharma. Nothing to Disclose: DJY, AMT</p><p>Sources of Research Support: Bayer Pharma AG partially funded data entry and statistical analyses.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 17164, member: 3"] [B] [B][URL="http://scholar.google.com/scholar_url?url=http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2015.RE.11.FRI-132&hl=en&sa=X&scisig=AAGBfm1yZaXU-LlC7E7PIyADSCe2Kz4V9Q&nossl=1&oi=scholaralrt"]FRI-132: Effects of Continuous Treatment up to 11 Years with [B]Testosterone Undecanoate Injections (TU) in 115 Hypogonadal [B]Men on Hormonal, Anthropometric and[/B][/B][/URL][/B][/B] [B]Abstract:[/B][B]Introduction:[/B] The longest-term follow-up on testosterone replacement therapy (TRT) in hypogonadal men in the literature is 6 years. In this registry study, we assessed effects of TRT beyond this period. [B]Methods:[/B] Single-center, cumulative, prospective, registry study of 262 hypogonadal men receiving TU for up to 11 years. Cut-off for total testosterone (T): ≤ 12 nmol/L (~350 ng/dl). In 147 men, TRT had been temporarily discontinued due to reimbursement issues or diagnosis of prostate cancer. In 115 men reported here, TRT was never interrupted for up to 11 years. 115 men were treated for a minimum of 4 years, 114 for 5, 97 for 6, 70 for 7, 57 for 8, 48 for 9, and 23 for 10 years. 4 patients dropped out, 2 due to relocation, 2 were lost to follow-up for unknown reasons. Measures were taken at every other visit. Results at the end of 10 years follow-up are reported. [B]Results:[/B] Mean age was 59.05 ± 9.36 years (min.: 19; max.: 80). Total T increased from 7.84 ± 2.34 nmol/L to trough levels (measured prior to the following injection) between 17 and 20 nmol/L, free T from 150.31 ± 65.24 to 400-500 pmol/L, and SHBG decreased from 40.12 ± 20.73 to 33.11 ± 22.14 nmol/L (p<0.0001). Mean waist circumference decreased from 106.47 ± 8.72 to 92.33 ± 5.32 cm. The decrease was statistically significant vs baseline (p<0.0001) and significant vs previous year for the first 7 years. Mean weight decreased from 97.3 ± 12.88 to 84.65 ± 7.04 kg. The decrease was statistically significant vs baseline (p<0.0001) and significant vs previous year for the first 8 years. Mean BMI decreased from 30.81 ± 4.33 to 27.06 ± 2.49 kg/m[SUP]2[/SUP] The decrease was statistically significant vs baseline (p<0.0001) and significant vs previous year for the first 8 years. Weight reduction was progressive and accumulated to 18.51 ± 6.46% after 10 years. The reduction of waist circumference was 11.98 ± 5.03%. Total cholesterol (TC) decreased from 251.15 ± 46.77 to 172.02 ± 12.09 mg/dl (p<0.0001 vs baseline, statistical significance vs previous year for the first 7 years), LDL from 156.9 ± 25.43 to 98.09 ± 17.62 (p<0.0001 vs baseline, statistical significance vs previous year for the first 3 years), triglycerides (TG) from 235.72 ± 89.26 to 158.04 ± 20.99 (p<0.0001 vs baseline, statistical significance vs previous year for the first 4 years). HDL increased from 42.41 ± 12.61 to 56.52 ± 6.34 mg/dl (p<0.0001 vs baseline, statistical significance vs previous year for the first 3 years). TC:HDL ratio improved from 6.59 ± 2.82 to 3.08 ± 0.33 (p<0.0001). Non-HDL cholesterol decreased from 208.74 ± 52.35 to 115.5 ± 11.31 mg/dl (p<0.0001, statistical significance vs previous year for the first 7 years). TG:HDL ratio improved from 6.24 ± 3.53 to 2.82 ± 0.38 (p<0.0001). No major adverse cardiovascular event (MACE) occurred during the entire observation time. [B]Conclusions:[/B] Long-term TRT improved anthropometric and lipid parameters in hypogonadal men in a meaningful and sustained fashion. Disclosure: AAY: Investigator, Bayer Schering Pharma. GD: statistical analyses, Bayer Schering Pharma. FS: Employee, Bayer Schering Pharma. Nothing to Disclose: DJY, AMT Sources of Research Support: Bayer Pharma AG partially funded data entry and statistical analyses. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Update on Aveed (Nebido- testosterone undecanoate- long acting testosterone)
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top